RT Journal Article
SR Electronic
T1 Integrated cross-study datasets of genetic dependencies in cancer
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.05.22.110247
DO 10.1101/2020.05.22.110247
A1 Clare Pacini
A1 Joshua M. Dempster
A1 Isabella Boyle
A1 Emanuel Gonçalves
A1 Hanna Najgebauer
A1 Emre Karakoc
A1 Dieudonne van der Meer
A1 Andrew Barthorpe
A1 Howard Lightfoot
A1 Patricia Jaaks
A1 James M. McFarland
A1 Mathew J. Garnett
A1 Aviad Tsherniak
A1 Francesco Iorio
YR 2021
UL http://biorxiv.org/content/early/2021/01/06/2020.05.22.110247.abstract
AB CRISPR-Cas9 viability screens are increasingly performed at a genome-wide scale across large panels of cell lines to identify new therapeutic targets for precision cancer therapy. Integrating the datasets resulting from these studies is necessary to adequately represent the heterogeneity of human cancers and to assemble a comprehensive map of cancer genetic vulnerabilities. Here, we integrated the two largest public independent CRISPR-Cas9 screens performed to date (at the Broad and Sanger institutes) by assessing, comparing, and selecting methods for correcting biases due to heterogeneous single guide RNA efficiency, gene-independent responses to CRISPR-Cas9 targeting originated from copy number alterations, and experimental batch effects. Our integrated datasets recapitulate findings from the individual datasets, provide greater statistical power to cancer- and subtype-specific analyses, unveil additional biomarkers of gene dependency, and improve the detection of common essential genes. We provide the largest integrated resources of CRISPR-Cas9 screens to date and the basis for harmonizing existing and future functional genetics datasets.Competing Interest StatementMJG, and FI receive funding from Open Targets, a public-private initiative involving academia and industry. MJG receives funding from AstraZeneca and performs consultancy for Sanofi. FI performs consultancy for the joint CRUK - AstraZeneca Functional Genomics Centre. AT is a consultant `for Tango Therapeutics and Cedilla Therapeutics. JMD, JM and AT receive funding from the Cancer Dependency Map Consortium, but no consortium member was involved in or influenced this study. All the other authors declare no competing interests.